These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 28840314)

  • 21. The clinical value of the albumin quotient in patients with neuromyelitis optica spectrum disorder.
    Chen B; Qin C; Tao R; Dong YJ; Ma X; Chen M; Wu LJ; Bu BT; Tian DS
    Mult Scler Relat Disord; 2020 Feb; 38():101880. PubMed ID: 31812873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuromyelitis optica spectrum disorders: still evolving and broadening.
    Fujihara K
    Curr Opin Neurol; 2019 Jun; 32(3):385-394. PubMed ID: 30893099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
    Fujihara K; Cook LJ
    Curr Opin Neurol; 2020 Jun; 33(3):300-308. PubMed ID: 32374571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
    Ungureanu A; de Seze J; Ahle G; Sellal F
    Rev Neurol (Paris); 2018 Dec; 174(10):675-679. PubMed ID: 30293882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder.
    Akaishi T; Takahashi T; Misu T; Kaneko K; Takai Y; Nishiyama S; Ogawa R; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakashima I
    Neurology; 2021 Jul; 97(1):e1-e12. PubMed ID: 33980704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.
    Ringelstein M; Ayzenberg I; Lindenblatt G; Fischer K; Gahlen A; Novi G; Hayward-Könnecke H; Schippling S; Rommer PS; Kornek B; Zrzavy T; Biotti D; Ciron J; Audoin B; Berthele A; Giglhuber K; Zephir H; Kümpfel T; Berger R; Röther J; Häußler V; Stellmann JP; Whittam D; Jacob A; Kraemer M; Gueguen A; Deschamps R; Bayas A; Hümmert MW; Trebst C; Haarmann A; Jarius S; Wildemann B; Grothe M; Siebert N; Ruprecht K; Paul F; Collongues N; Marignier R; Levy M; Karenfort M; Deppe M; Albrecht P; Hellwig K; Gold R; Hartung HP; Meuth SG; Kleiter I; Aktas O;
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34785575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease.
    Hamid SHM; Whittam D; Saviour M; Alorainy A; Mutch K; Linaker S; Solomon T; Bhojak M; Woodhall M; Waters P; Appleton R; Duddy M; Jacob A
    JAMA Neurol; 2018 Jan; 75(1):65-71. PubMed ID: 29131884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity.
    Chien C; Scheel M; Schmitz-Hübsch T; Borisow N; Ruprecht K; Bellmann-Strobl J; Paul F; Brandt AU
    Mult Scler; 2019 Dec; 25(14):1926-1936. PubMed ID: 30475082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of the 2015 neuromyelitis optica spectrum disorders diagnostic criteria in a cohort of Chinese patients.
    He M; Wu L; Huang D; Yu S
    Mult Scler Relat Disord; 2020 Nov; 46():102459. PubMed ID: 32853894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Joint radiomics and spatial distribution model for MRI-based discrimination of multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder.
    Luo X; Li H; Xia W; Quan C; ZhangBao J; Tan H; Wang N; Bao Y; Geng D; Li Y; Yang L
    Eur Radiol; 2024 Jul; 34(7):4364-4375. PubMed ID: 38127076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
    Wu Y; Zhong L; Geng J
    Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis.
    Li X; Zhang C; Jia D; Fan M; Li T; Tian DC; Liu Y; Shi FD
    Mult Scler Relat Disord; 2021 Aug; 53():103030. PubMed ID: 34118585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prevalence and clinical phenotype of dual seropositive neuromyelitis optica spectrum disorders at a national reference center in South Asia.
    Lalwani CS; Faisal F; Yadav A; Kannoth S; Nambiar V; Gopinath S; Kumar A; Umesh SU; Vincent J; Anoop S; Mathai A; Panicker S
    Mult Scler Relat Disord; 2023 Jul; 75():104736. PubMed ID: 37126965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases.
    Hofer LS; Ramberger M; Gredler V; Pescoller AS; Rostásy K; Sospedra M; Hegen H; Berger T; Lutterotti A; Reindl M
    Front Immunol; 2020; 11():1188. PubMed ID: 32625206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HLA association in MOG-IgG- and AQP4-IgG-related disorders of the CNS in the Dutch population.
    Bruijstens AL; Wong YYM; van Pelt DE; van der Linden PJE; Haasnoot GW; Hintzen RQ; Claas FHJ; Neuteboom RF; Wokke BHA
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32198229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
    Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
    JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates.
    Sepúlveda M; Aldea M; Escudero D; Llufriu S; Arrambide G; Otero-Romero S; Sastre-Garriga J; Romero-Pinel L; Martínez-Yélamos S; Sola-Valls N; Armangué T; Sotoca J; Escartín A; Robles-Cedeño R; Ramió-Torrentà L; Presas-Rodríguez S; Ramo-Tello C; Munteis E; Pelayo R; Gubieras L; Brieva L; Ortiz N; Hervás M; Mañé-Martínez MA; Cano A; Vela E; Tintoré M; Blanco Y; Montalban X; Graus F; Saiz A
    Mult Scler; 2018 Dec; 24(14):1843-1851. PubMed ID: 28984163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.